- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03341715
Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This project explores the effects of 1 dose of AZQ056, an experimental non-competitive antagonist to metabotropic glutamate receptor-5 (mGlur5) developed by Novartis, in a double-blind, randomized, counterbalanced manner on alcoholism risk-relevant tasks.
Drug/placebo will be administered on 2 separate visits separated by 1 week. More specifically, this project examines 4 functional MRI tasks related to different aspects of reward and/or impulsivity-related behavior in different contexts, compares the underlying neural circuitry across tasks, and uses a pharmacologic probe of the glutamatergic system to examine N-methyl-D-Aspartate and Dopamine (NMDA/DA) interactions.
The combined measures provide the opportunity to advance our understanding of specific aspects of brain function related to familial alcoholism vulnerability in an already well characterized population as some members evolve into alcohol abuse. In addition, as well as conventional within-task analyses, functional network connectivity and allied approaches will be used to examine brain networks across the above tasks.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06102
- Hartford Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects will be first screened toxicologically for drugs of abuse (and for women of childbearing age, pregnancy) by urine testing, any positive test results in exclusion.
- Participants will be able to understand the procedures as judged by their ability to clearly repeat back to the PI or his designee correctly, the purpose and content of the planned research, and willingly agree to participate.
Exclusion Criteria:
- a diagnosis of DSM-IV psychiatric disorder
- report of psychotic disorder in a 1º relative, auditory or visual impairment that interferes with test-taking
- prenatal exposure to alcohol plus currently meeting criteria for features of fetal alcohol syndrome
- not speaking English fluently or being a non-native English speaker, or being educated in a primary language other than English > grade 1
- mental retardation (Full Scale IQ<70)
- traumatic brain injury with loss of consciousness > 30 minutes or concussion in last 30 days
- presence or history of any medical/neurologic illness that may affect brain physiology (e.g., epilepsy, Multiple Sclerosis), including focal brain lesion seen on structural MRI (all structural scans are read by a licensed radiologist)
- current pregnancy (all females will be tested with urine screens on the day of MRI);
- All participants will receive a urine screen for the presence of marijuana, cocaine, opiates and a breath screen to detect the presence of alcohol
- Inability to comprehend the consent form appropriately
Other specific fMRI exclusions include metal devices, clips or fragments in body (orbital x-ray performed if needed).
- Individuals will be excluded who have taken, within the prior 14 days, the following strong inhibitors or inducers of CYP1A, CYP2C, and CYP3A and CYP3A4: iprofloxacin, enoxacin, fluvoxamine; gemfibrozil; fluconazole, fluvoxamine, ticlopidine; boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole; bupropion, fluoxetine, paroxetine, quinidine; avasimibe, carbamazepine, phenytoin, rifampin, and St. John's wort.
- Individuals will also be excluded who have taken, within 14 days, the following moderate inhibitors and inducers of CYP3A: Amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, and verapamil; and bosentan, efavirenz, etravirine, modafinil, and nafcillin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Mavoglurant (AFQ056)
The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
|
2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
|
PLACEBO_COMPARATOR: Placebo
The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
|
Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRI Monetary Incentive Delay (MID) task
Time Frame: 2 Hours post medication administration
|
BOLD activation during A1 phase of MID
|
2 Hours post medication administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRI Alcohol Cue Reactivity (ACR) task
Time Frame: 2 Hours post medication administration
|
BOLD signal activation in the fusiform area and hippocampus for the alcohol cue reactivity (ACR) task.
FHP individuals will show increased BOLD signal activation in the fusiform area and hippocampus to repeated alcohol images.
|
2 Hours post medication administration
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HHC-2017-0172
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Familial Alcoholism Vulnerability
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingFamilial Alcoholism VulnerabilityUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of Massachusetts, WorcesterNational Institute of Mental Health (NIMH); Albert Einstein College of Medicine and other collaboratorsNot yet recruitingDepression | Economic VulnerabilityBangladesh
-
National Institute on Drug Abuse (NIDA)WithdrawnConduct Disorder | Adolescents | Vulnerability to Substance Addicition
-
Kyunghee University Medical CenterCompletedIntraplaque Neovascularization Evaluated by Carotid Enhanced Ultrasound Well Reflect the Plaque VulnerabilityKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedDrug Addiction | Vulnerability to Substance AddictionUnited States
-
Assistance Publique Hopitaux De MarseilleNot yet recruiting
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Alnylam PharmaceuticalsCompletedATTR Amyloidosis | Transthyretin (TTR)-Mediated Amyloidosis | Familial Amyloidotic Polyneuropathy (FAP) | Familial Amyloid NeuropathiesFrance, Germany, Portugal, United Kingdom, Sweden, Spain
-
Leiden University Medical CenterJacobijn Gussekloo, Prof. dr.; Simon P. Mooijaart, Prof. dr.RecruitingAging | Extreme Longevity | Longevity | Familial LongevityNetherlands
Clinical Trials on Mavoglurant (AFQ056)
-
Elizabeth Berry-KravisNational Institute of Neurological Disorders and Stroke (NINDS); Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsTerminatedPatient Diagnosed With OCD and Resistant to SSRI Treatment | Failed SSRI Over 12 Weeks at Appropriate DosesGermany, Switzerland, Bulgaria, United States, Czech Republic
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingFamilial Alcoholism VulnerabilityUnited States
-
Novartis PharmaceuticalsCompletedCocaine-related DisorderSpain, Argentina, Switzerland
-
Novartis PharmaceuticalsTerminatedFragile X SyndromeGermany, United States, Switzerland, Australia, Canada, Denmark, France, Italy, United Kingdom, Spain
-
Novartis PharmaceuticalsCompletedFragile X SyndromeUnited States, Switzerland, Germany, Australia, Canada, Denmark, France, Italy, Spain, United Kingdom
-
Novartis PharmaceuticalsCompletedFragile X SyndromeUnited States, Spain
-
Novartis PharmaceuticalsCompletedMild Moderate | or Severe Renal ImpairmentGermany
-
Novartis PharmaceuticalsCompletedHepatic ImpairmentGermany, United States, Hungary
-
Novartis PharmaceuticalsTerminatedFragile X SyndromeUnited States, Belgium, Australia, Israel, Switzerland, Germany, Denmark, Italy, Netherlands, Spain, Sweden, United Kingdom, France